Building human renal tracts.


Journal

Journal of pediatric surgery
ISSN: 1531-5037
Titre abrégé: J Pediatr Surg
Pays: United States
ID NLM: 0052631

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 04 10 2021
accepted: 22 10 2021
pubmed: 29 11 2021
medline: 9 2 2022
entrez: 28 11 2021
Statut: ppublish

Résumé

Severe kidney failure affects several million people worldwide. Among these are children born with abnormal renal tracts, and some carry mutations of genes active in renal tract development. Kidney transplants are in short supply, and long term dialysis does not obviate uraemia and its associated harmful effects. It has been envisaged that a combination of stem cell technology, developmental biology, and genetics will revolutionise our understanding of kidney disease and provide novel therapies for kidney failure. Here, we review progress towards making functional kidney tissues from human pluripotent stem cells. Organoids rich in immature glomeruli and tubules can be created in culture from pluripotent stem cells. Moreover, differentiation can be increased by implanting these cells into immunodeficient mice. Challenges remain to be overcome, however, before these tissues can be used for regenerative medicine therapies. Current limitations include the small size of an organoid, the lack of large blood vessels feeding it, and the lack of a urinary tract to plumb the kidney organoid. Pluripotent stem cell technology is also being used to create 'diseases in a dish' to understand the pathobiology underlying human renal tract malformations.

Identifiants

pubmed: 34838308
pii: S0022-3468(21)00735-1
doi: 10.1016/j.jpedsurg.2021.10.022
pmc: PMC8837266
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

172-177

Subventions

Organisme : Medical Research Council
ID : MR/T016809/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Author. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The author declared no competing interests.

Références

Cell Stem Cell. 2017 Dec 7;21(6):730-746.e6
pubmed: 29129523
Stem Cell Reports. 2018 Mar 13;10(3):766-779
pubmed: 29429961
Cell Stem Cell. 2018 Dec 6;23(6):869-881.e8
pubmed: 30449713
Stem Cell Reports. 2021 Jan 12;16(1):134-148
pubmed: 33306987
Trends Biotechnol. 2018 Oct;36(10):1011-1024
pubmed: 29937050
Stem Cells Transl Med. 2014 May;3(5):610-9
pubmed: 24657961
J Pathol. 2019 Dec;249(4):472-484
pubmed: 31400222
Arch Pathol. 1964 May;77:502-9
pubmed: 14120685
Stem Cell Reports. 2018 Aug 14;11(2):470-484
pubmed: 30033089
Cell Stem Cell. 2021 Apr 1;28(4):671-684.e6
pubmed: 33378647
Cell Rep. 2020 Dec 15;33(11):108514
pubmed: 33326782
Cell Rep. 2020 Jul 28;32(4):107963
pubmed: 32726627
Lancet. 2015 May 16;385(9981):1975-82
pubmed: 25777665
J Am Soc Nephrol. 2001 Oct;12(10):2175-2180
pubmed: 11562418
Kidney Int. 1990 Nov;38(5):991-7
pubmed: 2266685
Front Pediatr. 2019 Apr 11;7:136
pubmed: 31032239
Development. 2008 Oct;135(19):3301-10
pubmed: 18776146
Curr Top Dev Biol. 2016;117:31-64
pubmed: 26969971
Ciba Found Symp. 1992;165:183-93; discussion 193-8
pubmed: 1516468
Kidney Int. 2019 Oct;96(4):871-882
pubmed: 31399199
Pediatr Nephrol. 2017 Feb;32(2):243-248
pubmed: 27115888
Kidney Int Rep. 2019 May 29;4(9):1304-1311
pubmed: 31517149
Arch Pathol. 1964 May;77:474-84
pubmed: 14120683
Differentiation. 2007 Dec;75(10):968-77
pubmed: 17490411
Pediatr Nephrol. 2010 Nov;25(11):2247-55
pubmed: 20603712
Stem Cell Reports. 2018 Mar 13;10(3):751-765
pubmed: 29503086
J Am Soc Nephrol. 2020 Oct;31(10):2253-2262
pubmed: 32826325
Pediatr Nephrol. 2012 Mar;27(3):363-73
pubmed: 21713524
J Am Soc Nephrol. 2013 Jan;24(1):19-25
pubmed: 23123402
Science. 1953 Jul 10;118(3054):52-5
pubmed: 13076182
Angiogenesis. 1997;1(1):84-101
pubmed: 14517396
Pediatr Nephrol. 2009 Oct;24(10):1913-9
pubmed: 19190936
Nephron. 2020;144(10):509-524
pubmed: 32756058
Sci Rep. 2019 Jul 19;9(1):10506
pubmed: 31324820
Nephron. 2021;145(3):285-296
pubmed: 33774632

Auteurs

Adrian S Woolf (AS)

Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Michael Smith Building, Faculty of Biology Medicine and Health, University of Manchester, Oxford Road, Manchester, Northern Ireland M13 9PT, United Kingdom; Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Center, Manchester, Northern Ireland, United Kingdom. Electronic address: adrian.woolf@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH